Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • The role of VEGF across tumor types 

    • VEGF in multiple myeloma 

    • Summary 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
        • VEGF in lung cancer
        • VEGF in colorectal cancer
        • VEGF in renal cell carcinoma
        • VEGF in glioblastoma
        • VEGF in ovarian cancer
        • VEGF in bladder cancer
        • VEGF in gastric cancer
        • VEGF in multiple myeloma
          • VEGF expression in multiple myeloma
          • VEGF pathways in multiple myeloma
          • VEGF and prognosis in multiple myeloma
          • Summary
        • VEGF in pancreatic cancer
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Clinical Trials
    • Multiple Myeloma
      • Multiple Myeloma
  • Cancer Biomarkers
    • Multiple Myeloma
      • Research BRAF
      • Glossary
      • BRAF in metastatic melanoma
      • Identifying BRAF mutations in melanoma
      • Oncogenic BRAF in melanoma subtypes
      • Oncogenic BRAF and prognosis
      • Oncogenic BRAF in cancer
      • Oncogenic BRAF in melanoma development
  • Future Directions
    • Antibody-Drug conjugates
      • A brief history of ADCs
      • Current research in ADCs
      • Cytotoxic agent
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • How are ADCs designed to work?
      • VEGF and prognosis in multiple myeloma
      • Glossary
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Monoclonal antibody
      • Multimedia Resources
      • Receptor-Mediated Endocytosis
      • Research ADCs
      • VEGF, MVD, and metastases in gastric carcinoma
      • Stable linker
      • Targeting cancers with ADCs
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
      • What are ADCs?
    • Glycoengineered Antibodies
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Non-Antibody Biologics
      • Apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Targeted Small Molecules
      • Apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • Glossary
      • VEGF expression and liver metastases
      • MAPK Signaling
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Multiple Myeloma
      • PI3K Inhibitor (GDC-0941)
      • VEGF, MVD, and metastases in gastric carcinoma
      • PI3K/Akt/mTOR Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Traditional Monoclonal Antibodies
      • B-cell Surface Proteins
      • Glossary
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • Angiogenic Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma

Video

Full VEGF & angiogenesis

View video now

Links

  • VEGF in NSCLC
  • VEGF in CRC
  • VEGF in RCC
  • VEGF in GBM
  • VEGF in ovarian cancer
  • VEGF in bladder cancer
  • VEGF in gastric cancer
  • VEGF in pancreatic cancer
Share

VEGF Role in Pathology of Multiple Myeloma

VEGF plays a central role in the pathology of multiple myeloma, contributing to the survival, proliferation, and diffusion of plasma cells with paracrine and autocrine mechanisms.1

As part of a complex interplay between bone marrow components and biological functions, VEGF affects more than just a single mechanism or pathway.2 Studies have shown that endothelial cells sustain growth in multiple myeloma not only by providing a vascular supply, but also by providing proliferation and survival stimuli for malignant plasma cells.3

VEGF and MVD, both indicators of angiogenesis, are accepted parameters in hematological tumors and are correlated with clinical outcomes.1

References:
1.
Ria R, Roccaro AM, Merchionne F, et al. Leukemia. 2003;17:1961-1966. PMID: 14513045
2.
Podar K, Anderson KC. Blood. 2005;105:1383-1395. PMID: 15471951
3.
Jakob C, Sterz J, Zavrski I, et al. Eur J Cancer. 2006;42:1581-1590. PMID: 16797965
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: VEGF in pancreatic cancer »

© 2011 Genentech USA, Inc. All rights reserved